1. Efficacy and safety of baricitinib in patients with refractory alopecia areata.
- Author
-
Wang, Yuqian, Liu, Taoming, Li, Sheng, Tang, Shunli, Lin, Peiyi, Ding, Yuwei, Sun, Qingmiao, Zhu, Dingxian, Qiao, Jianjun, and Fang, Hong
- Subjects
ALOPECIA areata ,PATIENT safety ,CLINICAL trials ,REFRACTORY materials - Abstract
At week 20, two patients (18%) achieved CR, six patients (55%) achieved PR, and three patients (27%) were evaluated as NR. The subtypes of AA included alopecia universalis in two patients, alopecia totalis in two patients, multiple AA in six patients, and alopecia ophiasis in one patient. Alopecia areata (AA) is an autoimmune disorder characterized by nonscarring hair loss.[1] Numerous treatment options are available for AA.[[2]] However, it is often challenging and unsatisfactory for refractory AA treatment. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF